News

Partner companies' news

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis
HANOVER, MD, April 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage bioph...
Acorn Management Partners, Administrator
— April 2022 — 423 views PCSA

KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
CELEBRATION, Fla., March 30, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company...
Acorn Management Partners, Administrator
— April 2022 — 454 views KMPH

Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage compa...
Acorn Management Partners, Administrator
— April 2022 — 427 views PCSA

KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference
CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery a...
Acorn Management Partners, Administrator
— March 2022 — 477 views KMPH

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST
HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing...
Acorn Management Partners, Administrator
— March 2022 — 419 views PCSA

KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
CELEBRATION, Fla., March 21, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (the Company or KemPharm), a specialty pharmaceutical company ...
Acorn Management Partners, Administrator
— March 2022 — 455 views KMPH

KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)
CELEBRATION, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), a specialty pharmaceutical company...
Acorn Management Partners, Administrator
— March 2022 — 433 views KMPH

Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference
HANOVER, MD, March 10, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage bioph...
Acorn Management Partners, Administrator
— March 2022 — 437 views PCSA

KemPharm to Report Fourth Quarter and Full-Year 2021 Results
CELEBRATION, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery a...
Acorn Management Partners, Administrator
— March 2022 — 477 views KMPH

KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
CELEBRATION, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— February 2022 — 462 views KMPH

KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
CELEBRATION, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— January 2022 — 447 views KMPH

KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
CELEBRATION, Fla., Jan. 12, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— January 2022 — 464 views KMPH

KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference
CELEBRATION, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— January 2022 — 455 views KMPH

KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”
CELEBRATION, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— January 2022 — 485 views KMPH

KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
CELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— December 2021 — 516 views KMPH

KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
CELEBRATION, Fla., Dec. 14, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and ...
Acorn Management Partners, Administrator
— December 2021 — 474 views KMPH

KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida
CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and ...
Acorn Management Partners, Administrator
— December 2021 — 515 views KMPH

About us

Helping America invest in you:

Connecting your company stock with professional market participants.

One call at a time

Stay updated :

Participate on our social stream.

Our Blogs

Tags

Archives